{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit was not reached due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"6.5","upperLimit":"NA","value":"39.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"The time from the start of CR or PR to the first date of documented PD or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.","id":"OG000","title":"Experimental: Nab-Sirolimus"}],"paramType":"MEDIAN","populationDescription":"Patients with a confirmed partial or complete response","reportingStatus":"POSTED","timeFrame":"From Initial response until tumor progression, through study completion (up to 72 months)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}